drugset / Trial / NCT03150316
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D) based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Lenalidomide and Dexamethasone in patients with Previously Treated Multiple Myeloma.
Timeline
- Start
- 2017-05-10
- Primary completion
- 2020-06-30
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALTEMINOSTAT | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |